Advertisement
IMUX vs VYGR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMUX is a Hold and VYGR is a Buy.
IMUX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for IMUX turned positive on October 15, 2026. Looking at past instances where IMUX's MACD turned positive, the stock continued to rise in 37 of 41 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMUX's RSI Indicator exited the oversold zone, 27 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on IMUX as a result. In 72 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
Following a +3.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMUX advanced for three days, in 212 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for IMUX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMUX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for IMUX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.829) is normal, around the industry mean (3.498). P/E Ratio (-2.183) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. IMUX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMUX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for VYGR turns positive, indicating new upward trend
VYGR saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned positive. In 85 of the 95 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VYGR's RSI Oscillator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 61 cases where VYGR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for VYGR just turned positive on October 30, 2026. Looking at past instances where VYGR's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Following a +15.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where VYGR advanced for three days, in 228 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
VYGR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VYGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for VYGR entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.744) is normal, around the industry mean (3.498). P/E Ratio (-1.030) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.263) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. VYGR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VYGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
IMUX | VYGR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | 47 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 98 | |
PRICE GROWTH RATING 1..100 | 64 | 85 | |
P/E GROWTH RATING 1..100 | 10 | 12 | |
SEASONALITY SCORE 1..100 | 50 | 49 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IMUX's Valuation (31) in the Pharmaceuticals Major industry is in the same range as VYGR (47) in the Biotechnology industry. This means that IMUX’s stock grew similarly to VYGR’s over the last 12 months.
IMUX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as VYGR (100) in the Biotechnology industry. This means that IMUX’s stock grew similarly to VYGR’s over the last 12 months.
VYGR's SMR Rating (98) in the Biotechnology industry is in the same range as IMUX (99) in the Pharmaceuticals Major industry. This means that VYGR’s stock grew similarly to IMUX’s over the last 12 months.
IMUX's Price Growth Rating (64) in the Pharmaceuticals Major industry is in the same range as VYGR (85) in the Biotechnology industry. This means that IMUX’s stock grew similarly to VYGR’s over the last 12 months.
IMUX's P/E Growth Rating (10) in the Pharmaceuticals Major industry is in the same range as VYGR (12) in the Biotechnology industry. This means that IMUX’s stock grew similarly to VYGR’s over the last 12 months.
| IMUX | VYGR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 84% | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 87% |
| Momentum ODDS (%) | 2 days ago 89% | 2 days ago 89% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 84% |
| Advances ODDS (%) | 2 days ago 84% | 3 days ago 83% |
| Declines ODDS (%) | 10 days ago 86% | 13 days ago 82% |
| BollingerBands ODDS (%) | N/A | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 71% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMUX’s FA Score shows that 2 FA rating(s) are green while VYGR’s FA Score has 1 green FA rating(s).
- IMUX’s FA Score: 2 green, 3 red.
- VYGR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMUX’s TA Score shows that 4 TA indicator(s) are bullish while VYGR’s TA Score has 6 bullish TA indicator(s).
- IMUX’s TA Score: 4 bullish, 4 bearish.
- VYGR’s TA Score: 6 bullish, 2 bearish.
Price Growth
IMUX (@Biotechnology) experienced а +5.79% price change this week, while VYGR (@Biotechnology) price change was -0.27% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
IMUX is expected to report earnings on Nov 12, 2026.
VYGR is expected to report earnings on Mar 09, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IMUX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMUX has been loosely correlated with WHWK. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if IMUX jumps, then WHWK could also see price increases.
| Ticker / NAME | Correlation To IMUX | 1D Price Change % | ||
|---|---|---|---|---|
| IMUX | 100% | +1.01% | ||
| WHWK - IMUX | 38% Loosely correlated | -4.35% | ||
| VYGR - IMUX | 37% Loosely correlated | -8.29% | ||
| EDIT - IMUX | 36% Loosely correlated | -8.91% | ||
| SGMT - IMUX | 36% Loosely correlated | +0.55% | ||
| CCCC - IMUX | 35% Loosely correlated | -4.76% | ||
More | ||||
VYGR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VYGR has been loosely correlated with EDIT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if VYGR jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To VYGR | 1D Price Change % | ||
|---|---|---|---|---|
| VYGR | 100% | -8.29% | ||
| EDIT - VYGR | 60% Loosely correlated | -8.91% | ||
| RCKT - VYGR | 55% Loosely correlated | -3.16% | ||
| DYN - VYGR | 52% Loosely correlated | -3.76% | ||
| MGTX - VYGR | 50% Loosely correlated | +1.37% | ||
| SLDB - VYGR | 50% Loosely correlated | +2.14% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HERZ | 15.25 | N/A | N/A |
| Herzfeld Credit Income Fund Inc. | |||
| KBAB | 6.45 | N/A | N/A |
| KraneShares 2x Long BABA Daily ETF (KBAB) | |||
| TPZ | 20.25 | -0.06 | -0.28% |
| Tortoise Electrification Infrastructure ETF (TPZ) | |||
| XSOE | 42.22 | -0.24 | -0.57% |
| WisdomTree Emerging Markets ex-State-Owned Enterprises Fund (XSOE) | |||
| FDNI | 26.14 | -0.39 | -1.47% |
| First Trust Dow Jones International Internet ETF (FDNI) | |||